| | |
Alembic Pharmaceuticals today said it along with Breckenridge Pharmaceutical Inc, USA has settled patent case with Novartis for Rivastigmine Tartrate capsules used for treating dementia.
The companies have settled their Paragraph IV patent litigation with Novartis for Rivastigmine Tartrate capsules which are a generic version of Exelon capsules of Novartis, Alembic Pharmaceuticals said in a filing to BSE.
Under the terms of the settlement agreement, Novartis has granted the two companies a licence to market their generic capsules before the date of the patent expiry, it added. The companies will launch the product immediately in the American market, Alembic Pharmaceuticals said.
United States Food and Drug Administration (USFDA) has approved their abbreviated new drug application (ANDA). While the Indian firm is the sponsor and manufacturer of the ANDA, the product will be marketed exclusively by Breckenridge.
Rivastigmine Tartrate capsules are prescribed for mild to moderate dementia of Alzheimer's type and mild to moderate dementia associated with Parkinson's disease, the company said. The product will be available in the strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg, it added.
Shares of Alembic Pharmaceuticals today closed at Rs 53.70 a piece on BSE, up a steep 4.58% from its previous close.
Alembic Pharma stock price
On September 30, 2014, Alembic Pharmaceuticals closed at Rs 413.15, down Rs 7.05, or 1.68 percent. The 52-week high of the share was Rs 449.70 and the 52-week low was Rs 136.50.
The company's trailing 12-month (TTM) EPS was at Rs 13.28 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 31.11. The latest book value of the company is Rs 33.40 per share. At current value, the price-to-book value of the company is 12.37.
Set email alert for
ADS BY GOOGLE
video of the day
Barring IT & pharma, Q2 earnings to disappoint: Dimensions